2024
Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience
Varga C, Robinson M, Ehsan H, Roberts D, Dicamillo S, Gupta V, Borden S, Bhutani M, Paul B, Atrash S, Ferreri C, Nooka A, Voorhees P, Joseph N. Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide(Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Real World Experience. Transplantation And Cellular Therapy 2024, 30: s377-s378. DOI: 10.1016/j.jtct.2023.12.528.Peer-Reviewed Original ResearchNewly diagnosed multiple myelomaLevine Cancer InstituteStem cell yieldNewly diagnosed multiple myeloma patientsStem cell collectionStem cell mobilizationInduction therapyG-CSFDose of G-CSFTransplant-eligible NDMM patientsCell mobilizationCycles of induction therapyCell collectionCancer InstituteCD34+ cells/kgMRD-negative statusMedian patient ageStem cell harvestWinship Cancer InstituteCD34+ cellsGrowth colony-stimulating factorColony-stimulating factorNDMM patientsGoal dosePatient age
2023
Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD)
Joseph N, Kaufman J, Dicamillo S, Roberts D, Gupta V, Hofmeister C, Dhodapkar M, Boise L, Lonial S, Nooka A. Comparison of Response and Survival Outcomes in Standard- and High-Risk Newly Diagnosed Transplant-Eligible Multiple Myeloma (NDMM) Patients Treated with Lenalidomide, Bortezomib and Dexamethasone (RVD) Versus Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVD). Blood 2023, 142: 647. DOI: 10.1182/blood-2023-187339.Peer-Reviewed Original ResearchStandard-risk patientsHigh-risk patientsOverall response rateRisk patientsPFS benefitInduction therapyHR patientsInduction regimenMyeloma patientsNDMM patientsTransplant-eligible multiple myeloma patientsInternational Myeloma Working Group Uniform Response CriteriaHigh-risk MM patientsEffective induction regimenHigh-risk cytogeneticsCombination of lenalidomideHigh-risk diseaseMultiple myeloma patientsUniform response criteriaDepth of responseLong-term outcomesEvidence of benefitMaintenance therapyOS benefitClinical characteristicsEfficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma
Kaufman J, Joseph N, Gupta V, Dicamillo S, Roberts D, Hofmeister C, Dhodapkar M, Nooka A, Lonial S, Boise L. Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma. Blood 2023, 142: 4699. DOI: 10.1182/blood-2023-181783.Peer-Reviewed Original ResearchStandard-risk patientsVGPR ratesRisk patientsPart of inductionInduction therapyMyeloma patientsNDMM patientsInternational Myeloma Working Group Uniform Response CriteriaStage 3 patientsCombination of lenalidomideHigh-risk patientsPhase 3 studyCohort of patientsUniform response criteriaDistinct clinical presentationsFree light chainsInstitutional review boardLenalidomide maintenanceMedian OSMedian PFSRVD inductionLast followClinical characteristicsOverall survivalPatient characteristics